Filter Results:
(6)
Show Results For
- All HBS Web
(24)
- Faculty Publications (6)
Show Results For
- All HBS Web
(24)
- Faculty Publications (6)
Page 1 of 6
Results
- July 2024
- Case
Gates Ventures: Making Alzheimer's a Forgotten Past
By: Satish Tadikonda, William Marks, Shardule Shah and Calvin Marambo
After a personal journey and interest in Alzheimer's Disease (AD) by Bill Gates, Gates Ventures set out to find the best way to accelerate innovation in the field of AD. In partnership with the Alzheimer's Drug Discovery Foundation, Gates Ventures created the... View Details
Keywords: Philanthropy and Charitable Giving; Entrepreneurial Finance; Health Disorders; Mission and Purpose
Tadikonda, Satish, William Marks, Shardule Shah, and Calvin Marambo. "Gates Ventures: Making Alzheimer's a Forgotten Past." Harvard Business School Case 824-075, July 2024.
- June 2023 (Revised July 2024)
- Case
Biogen and the Aduhelm Melee
By: Amitabh Chandra and Lauren Gunasti
Alzheimer's Disease is a devastating condition affecting millions of Americans. At this time, there is no cure. In 2021, Biogen's Aduhelm (aducanumab) received FDA approval under the accelerated approval pathway after a controversial approval process.
This... View Details
This... View Details
Keywords: Health Testing and Trials; Governing Rules, Regulations, and Reforms; Valuation; Product Development; Pharmaceutical Industry
Chandra, Amitabh, and Lauren Gunasti. "Biogen and the Aduhelm Melee." Harvard Business School Case 623-046, June 2023. (Revised July 2024.)
- 2020
- Working Paper
What Can Economics Say About Alzheimer's Disease?
By: Amitabh Chandra, Courtney Coile and Corina Mommaerts
Alzheimer’s Disease (AD) affects one in ten people aged 65 or older and is the most expensive disease in the United States. We describe the central economic questions raised by AD. While there is overlap with the economics of aging, the defining features of the... View Details
Chandra, Amitabh, Courtney Coile, and Corina Mommaerts. "What Can Economics Say About Alzheimer's Disease?" NBER Working Paper Series, No. 27760, August 2020.
- May 2017
- Teaching Plan
Neurotrack and the Alzheimer's Puzzle
By: Richard G. Hamermesh and Carin-Isabel Knoop
Teaching Note for HBS No. 816-072. View Details
- February 2016 (Revised September 2017)
- Case
Neurotrack and the Alzheimer's Puzzle
By: Richard G. Hamermesh, Liz Kind and Carin-Isabel Knoop
Elli Kaplan founded Neurotrack in 2012 with a breakthrough noninvasive cognitive diagnostics test that will detect Alzheimer's disease in its earliest pre-symptomatic stages. While the company has gained great traction in the three years since it was started, with no... View Details
Keywords: Alzheimer's Disease; Diagnostics; Healthcare; Entrepreneurship; Health Disorders; Science-Based Business; Business Model; Medical Devices and Supplies Industry; United States
Hamermesh, Richard G., Liz Kind, and Carin-Isabel Knoop. "Neurotrack and the Alzheimer's Puzzle." Harvard Business School Case 816-072, February 2016. (Revised September 2017.)
- October 2014 (Revised September 2017)
- Case
The National Football League and Brain Injuries
By: Richard G. Hamermesh and Matthew G. Preble
The National Football League (NFL) was both the most popular spectator sport in the U.S. and a major economic entity, taking in roughly $10 billion a year in revenue. However through the early twenty-first century, an increased understanding of the long-term effects of... View Details
Keywords: Employee Safety; Safety; Employees; Sports; Health; Ethics; Sports Industry; United States
Hamermesh, Richard G., and Matthew G. Preble. "The National Football League and Brain Injuries." Harvard Business School Case 815-071, October 2014. (Revised September 2017.)